| Stem definition | Drug id | CAS RN |
|---|---|---|
| 2282 | 500-92-5 |
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 9.09 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| BA (Bioavailability) | 60 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 14, 2000 | FDA | GLAXOSMITHKLINE |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Malaria | 111.55 | 33.28 | 15 | 931 | 205 | 63487871 |
| Dermatitis acneiform | 44.09 | 33.28 | 11 | 935 | 4985 | 63483091 |
| Exposure during pregnancy | 34.67 | 33.28 | 24 | 922 | 155523 | 63332553 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Malaria | 89.27 | 33.25 | 13 | 775 | 210 | 34955933 |
| Plasmodium falciparum infection | 45.50 | 33.25 | 6 | 782 | 44 | 34956099 |
| Hallucination | 44.16 | 33.25 | 22 | 766 | 51476 | 34904667 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Malaria | 139.23 | 30.62 | 20 | 1308 | 402 | 79742658 |
| Plasmodium falciparum infection | 43.15 | 30.62 | 6 | 1322 | 94 | 79742966 |
| Dermatitis acneiform | 35.31 | 30.62 | 11 | 1317 | 9982 | 79733078 |
| Pyrexia | 34.72 | 30.62 | 49 | 1279 | 678660 | 79064400 |
| Hallucination | 31.72 | 30.62 | 19 | 1309 | 85726 | 79657334 |
None
| Source | Code | Description |
|---|---|---|
| ATC | P01BB01 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Biguanides |
| ATC | P01BB51 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Biguanides |
| ATC | P01BB52 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Biguanides |
| FDA MoA | N0000000191 | Dihydrofolate Reductase Inhibitors |
| FDA EPC | N0000175482 | Antimalarial |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000962 | Antimalarials |
| MeSH PA | D000963 | Antimetabolites |
| MeSH PA | D000977 | Antiparasitic Agents |
| MeSH PA | D000981 | Antiprotozoal Agents |
| MeSH PA | D009676 | Noxae |
| CHEBI has role | CHEBI:35820 | antiprotozoal drugs |
| CHEBI has role | CHEBI:38068 | antimalarials |
| CHEBI has role | CHEBI:50683 | dihydrofolic acid reductase inhibitors |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Falciparum malaria | indication | 62676009 | DOID:14067 |
| Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention | indication | ||
| Plasmodium Falciparum Malaria Prevention | indication | ||
| Vivax malaria | off-label use | 27052006 | DOID:12978 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Hyperglycemia | contraindication | 80394007 | DOID:4195 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Chronic diarrhea | contraindication | 236071009 | |
| Vomiting | contraindication | 422400008 | |
| Malabsorption States | contraindication |
None
None
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.73 | Basic |
| pKa2 | 2.36 | Basic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Bifunctional dihydrofolate reductase-thymidylate synthase | Enzyme | INHIBITOR | DRUGBANK | CHEMBL | |||||
| Bifunctional dihydrofolate reductase-thymidylate synthase | Enzyme | WOMBAT-PK | |||||||
| Bifunctional dihydrofolate reductase-thymidylate synthase | Enzyme | WOMBAT-PK | |||||||
| Trace amine-associated receptor 1 | GPCR | EC50 | 5.27 | CHEMBL |
| ID | Source |
|---|---|
| 4021225 | VUID |
| N0000148669 | NUI |
| D02487 | KEGG_DRUG |
| 637-32-1 | SECONDARY_CAS_RN |
| 4021225 | VANDF |
| C0008241 | UMLSCUI |
| CHEBI:8455 | CHEBI |
| CHEMBL1201059 | ChEMBL_ID |
| CHEMBL1377 | ChEMBL_ID |
| DB01131 | DRUGBANK_ID |
| D002727 | MESH_DESCRIPTOR_UI |
| 6178111 | PUBCHEM_CID |
| 9676 | IUPHAR_LIGAND_ID |
| 418 | INN_ID |
| S61K3P7B2V | UNII |
| 142428 | RXNORM |
| 15669 | MMSL |
| d04593 | MMSL |
| 002942 | NDDF |
| 002943 | NDDF |
| 16970001 | SNOMEDCT_US |
| 387094004 | SNOMEDCT_US |
| 395845004 | SNOMEDCT_US |
| XEW | PDB_CHEM_ID |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| MALARONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0675 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 24 sections |
| MALARONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0675 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 24 sections |
| MALARONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0675 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 24 sections |
| MALARONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0676 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 24 sections |
| MALARONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0676 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 24 sections |
| MALARONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0173-0676 | TABLET, FILM COATED | 25 mg | ORAL | NDA | 24 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-4160 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 27 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-4160 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 27 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-4162 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 27 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0378-4162 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 27 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 10544-909 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 33261-900 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42254-150 | TABLET | 100 mg | ORAL | ANDA | 20 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43063-393 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43063-393 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
| Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43063-522 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 26 sections |
| Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43063-522 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 26 sections |
| Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43063-522 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 26 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1302 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-1302 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
| Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-2980 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 27 sections |
| Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-2980 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 27 sections |
| Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50090-2980 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 27 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-6393 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 22 sections |
| MALARONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 55289-747 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 24 sections |
| MALARONE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 55289-747 | TABLET, FILM COATED | 100 mg | ORAL | NDA | 24 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 60760-498 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63187-879 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
| Atovaquone and Proguanil Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63187-879 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 26 sections |
| Atovaquone and Proguanil HCl | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-5531 | TABLET, FILM COATED | 100 mg | ORAL | NDA authorized generic | 26 sections |